If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
172
results.
Updated on
27/07/2026 [08:08:00]
Results 150 to 172 of 172
Absstract of: RO139568A2
The invention relates to a portable measuring device allowing simultaneous electrochemical detection of lactate and glucose from sweat. According to the invention, the device comprises a small PC module (a) for instrument control, provided with software with graphical interface for representation and control of adjacent modules, namely: an electrochemical measuring module (b) provided with an analog multiplexing module (c) accommodating a screen-printed dual electrode array (d) mounted on wearable tapes that can be applied on the body and, in certain cases, a microfluidic module (e) that ensures sweat sampling and transfer to the measuring cell.
Absstract of: CN122117327A
The invention relates to the technical field of intelligent wearing and medical health, in particular to an intelligent paper diaper flexible sensing data analysis method and system, and the method comprises the steps: collecting a urine electric signal through a flexible sensor array integrated with a nano sensitive material, removing the motion and environmental noise interference through a self-adaptive filtering algorithm, and carrying out the analysis of the urine electric signal. Converting weak signals into biochemical index concentrations of urine sugar, uric acid and the like; further, multi-dimensional data such as urination duration and water intake are combined and input into a chronic disease evolution model constructed based on machine learning for analysis, and real-time monitoring and early warning of risks of chronic diseases such as diabetes mellitus and nephropathy are achieved. The problems that traditional urine detection is greatly interfered by the environment, data lags behind and continuous monitoring is lacked are solved, and the intelligent and precise level of nursing of disabled people is greatly improved.
Absstract of: CN122109250A
The invention relates to the technical field of human body chemical signal detection. The invention provides a sweat glucose concentration calibration method. The sweat glucose concentration calibration method comprises the following steps: step 1, acquiring basic data, sweat pH value and sweat glucose concentration of sweat glucose detection equipment; 2, respectively calibrating the sweat secretion rate and the sensor sensitivity based on the sweat pH value so as to calibrate the response current; and step 3, constructing a calibration formula, and inputting the basic data, the sweat pH value, the sweat glucose concentration, the calibrated response current and the sensor sensitivity into the calibration formula to obtain the calibrated sweat glucose concentration. According to the method, the glucose concentration of the sweat is calibrated by adopting a marker pH of the sweat, so that the problems that the glucose concentration of the sweat is lower and the concentration detection interference is more are effectively solved, and the recognition of a blood glucose chemical signal is better realized.
Absstract of: CN122096699A
The invention relates to the technical field of medical diagnosis, in particular to a tongue diagnosis system for screening diabetes mellitus, which comprises a tongue sensing module for collecting tongue physiological data, oral environment parameters and user basic health information; the dynamic tongue twinborn construction module constructs a digital twinborn, and simulates the physiological state change of the tongue through a microcirculation evolution algorithm to obtain simulation data; the intelligent analysis center is based on simulation data and combines with an improved Transform-CNN model to identify diabetes-related tongue abnormal features and assess risk levels; the visual interaction unit constructs an interactive virtual tongue picture scene, renders a tongue shape, metabolite distribution and a microcirculation state in real time, and generates a screening report and an intervention suggestion; the self-adaptive screening regulation and control unit predicts the diabetes trend and dynamically adjusts the screening frequency and the intervention scheme according to the diabetes risk level and the diabetes screening report. Therefore, the problems of low precision, poor adaptability and the like in the prior art are solved.
Absstract of: CN122104562A
The invention provides an application of zeaxanthin in preparation of a product for improving an oocyte in-vitro maturation defect caused by diabetes mellitus, relates to the technical field of biomedicine, and finds and verifies that the zeaxanthin has a remarkable improvement effect on the oocyte in-vitro maturation defect caused by diabetes mellitus for the first time; according to the culture solution, the in-vitro maturation rate of the diabetes oocytes can be increased, the quality of the oocytes can be improved from a plurality of key links, and the development potential of the oocytes is comprehensively improved. The culture solution is clear in component and simple in preparation method, the zeaxanthin is a natural compound, the biosafety is high, industrial production is easy to realize, the zeaxanthin can be directly applied to an oocyte culture process related to assisted reproduction and in-vitro fertilization, and the zeaxanthin has an important transformation value for clinical treatment of diabetic female infertility. Through strict animal experiments, cell culture, immunofluorescence staining and other detection technologies, the action effects of zeaxanthin and the special culture solution are systematically verified, the experimental design is strict, and the result is reliable.
Absstract of: CN122097400A
The invention discloses application of CO1-NUMT-lncRNA in preparation of drugs for treating diabetic cardiomyopathy as well as a product and a preparation method of the CO1-NUMT-lncRNA, and belongs to the field of biological medicines. The invention provides an application of CO1-NUMT-lncRNA (Ribonucleic Acid) in the aspect of preparing a medicine for resisting diabetic cardiomyopathy. The CO1-NUMT-lncRNA is as shown in SEQ ID NO. 1. Based on the application, the invention also provides a recombinant expression vector, a transformant and an anti-diabetic cardiomyopathy drug based on the CO1-NUMT-lncRNA and a pharmaceutical application of the CO1-NUMT-lncRNA, and provides a preparation method of the anti-diabetic cardiomyopathy drug. Animal experiments prove that the medicine for resisting diabetic cardiomyopathy provided by the invention can obviously improve the heart function of animals with diabetic cardiomyopathy, and plays an effective role in resisting diabetic cardiomyopathy.
Absstract of: CN122104567A
The invention discloses an exosome rich in miRNA-21-5p as well as a preparation method and application of the exosome. The preparation method comprises the following steps: culturing mesenchymal stem cells in a culture medium containing an accelerant, collecting supernate, and separating to obtain an exosome rich in miRNA-21-5p; the accelerant comprises at least one of vascular cell adhesion molecule-1, a tumor necrosis factor alpha and interleukin-6. According to the method, the exosome rich in miRNA-21-5p can be obtained; the exosome has a treatment effect on diabetic foot ulcer, and the treatment effect is obviously better than that of the exosome prepared by a traditional method.
Absstract of: CN122096785A
The invention relates to the technical field of Internet of Things and biomedical sensing, and discloses a passive UHF RFID-based non-invasive blood glucose concentration detection method, which comprises the following steps of: fixing a passive UHF RFID tag on a body surface preset monitoring part of a living experimental animal; the living experimental animal is placed in a wireless signal reading area constructed by an RFID reader and an antenna of the RFID reader; and performing exogenous blood sugar regulation on the living experimental animal, so that the blood sugar concentration in the living experimental animal generates dynamic change covering a normal blood sugar concentration range. A set of standardized and systematized blood glucose detection process is constructed, from early-stage preparation of experimental animals, exogenous blood glucose regulation and control, synchronous acquisition of signals and blood glucose reference values, preprocessing of a data set and establishment of a quantitative model, all the steps are closely connected, operation is normative, various random interferences in a living experiment are effectively inhibited, and the accuracy of blood glucose detection is improved. And the reliability and the stability of detection data are ensured.
Absstract of: CN122122673A
A method for generating a diabetes management parameter user interface, the method including providing stored program instructions of a first diabetes management application (DMA) configured to be stored in a memory of an electronic device and, when executed by a processor, generating a diabetes management parameter user interface for the first DMA, the first DMA is configured to: generate a first output display of a plurality of diabetes management parameters corresponding to a time series of analyte data, the plurality of diabetes management parameters depicting a trend of diabetes management parameter levels over time; generating a graphical indicator of a link to a second DMA stored in the memory; and activate the second DMA in response to an input selection of the link, where the second DMA is configured to be executed by the processor to generate a second output display of a current time diabetes management parameter corresponding to the temporal sequence of analyte data stored in the memory.
Absstract of: CN122104597A
The invention relates to the technical field of biology, in particular to a mesenchymal stem cell, an exosome, a preparation method and application. According to the mesenchymal stem cell (Nrf2-hUMSC) for overexpressing the Nrf2 gene provided by the invention, the survival rate and the functional stability of the mesenchymal stem cell in an oxidative stress environment are remarkably enhanced; the exosome (Nrf2-Exos) secreted by the Nrf2-hUMSC inherits the enhancement characteristic of a mother cell, a diabetic chronic wound animal model verifies that the Nrf2 antioxidant defense pathway of the local wound can be effectively activated by applying the Nrf2-hUMSC or the Nrf2-Exos, tissue repair is synergistically promoted, wound healing is remarkably accelerated, and the curative effect of the Nrf2-Exos is superior to that of unmodified mesenchymal stem cells. The Nrf2-hUMSC or Nrf2-Exos provided by the invention provides a set of complete and innovative treatment scheme from genetically engineered cells to acellular exosomes for the treatment of chronic refractory skin wounds.
Absstract of: CN122097124A
The invention discloses a diabetes mellitus metabolism coat vibration magnetic module control system and method, applied to a diabetes mellitus metabolism coat, the diabetes mellitus metabolism coat comprises a straitjacket, and a spine skeletal muscle group vibration module, a lumbar muscle group vibration module, an abdominal muscle group vibration module and a Zimen acupoint vibration magnetic module which are configured on the straitjacket, and further comprises a control terminal; wherein the control terminal comprises a control unit, and a parameter acquisition unit, a module driving unit, a state monitoring unit, a man-machine interaction unit, a data storage unit and a fault early warning protection unit which are electrically connected with the control unit. The control unit is arranged, the standard physiotherapy parameter model is built in, automatic adaptation of vibration and vibration magnetic parameters is achieved according to the user heart rate and body temperature physiological parameters collected by the parameter collection unit, the limitation of existing fixed parameter driving is broken through, individual differences of different users are adapted, and the pertinence and effectiveness of physiotherapy are greatly improved.
Absstract of: US20260144811A1
0000 A hydrogel for treatment of body cavity injury is derived from a chitosan derivative in which an aldonic acid is bound to an amino group of a glucosamine unit of chitosan by dehydration condensation. The hydrogel for treatment of body cavity injury has a granular shape. The hydrogel is injected into a body cavity using an injection device, and used for wound treatment of the body cavity. A kit for treatment of body cavity injury includes: an injection device; a tube to be connected to the injection device; and a hydrogel for treatment of body cavity injury, filled in the injection device and having a granular shape; wherein the hydrogel for treatment of body cavity injury is derived from a chitosan derivative in which an aldonic acid is bound to an amino group of a glucosamine unit of chitosan by dehydration condensation.
Absstract of: US20260144934A1
0000 A portable infusion pump can communicate with glucose monitor, such as a continuous glucose monitor (CGM), to receive continuous feedback relating to a user's blood glucose level during insulin or other medicament therapy and can automatically deliver insulin to a user when the CGM data indicates a need for additional insulin. Due to potential unreliability in the correlation of the CGM data to the user's actual blood glucose level, risk mitigation can be employed to limit the amount of extra insulin that can be delivered by the pump in response to the CGM data.
Absstract of: WO2026107790A1
Disclosed in the present invention is a blood glucose management system for establishing a wireless communication connection on the basis of signal strength. A signal strength threshold is preset in the blood glucose management system. During a period when a monitoring module and/or an infusion module is powered on and sends a broadcast signal, a program module searches for a nearby broadcast signal and identifies the signal strength of the broadcast signal. When the signal strength of the broadcast signal is not less than the preset signal strength threshold, the program module can establish a wireless communication connection with the monitoring module and/or the infusion module that sends the broadcast signal, without the need to input a device identifier of the monitoring module and/or the infusion module. Moreover, since the broadcast signal identified by the program module is sufficiently strong, it means that the program module is in proximity to the monitoring module and/or the infusion module that sends the broadcast signal, thereby ensuring the reliability of the program module establishing a wireless communication connection with a patient's own monitoring module and/or infusion module.
Absstract of: WO2026109522A1
Apparatuses, systems, and techniques are described to integrate the operations of a computational platform with a third-party application. The computational platform can perform operations related to medical data and non-medical data. The medical data can be routed to services that comply with one or more first regulatory frameworks. The non-medical data can be routed to services that comply with one or more second regulatory frameworks. The medical data can be related to the treatment and care of diabetes.
Absstract of: WO2026107792A1
A blood glucose management system, comprising: in a first operation mode, a program module (101) identifies the signal intensity of a broadcast signal; when the signal intensity of the broadcast signal is not less than a preset signal intensity threshold, the program module (101) establishes a wireless communication connection with a measurement module (100) and/or an infusion module (102) that sends the broadcast signal; in a second operation mode, a device identifier of the measurement module (100) and/or the infusion module (102) is inputted so as to establish the wireless communication connection.
Absstract of: US20260144928A1
0000 Provided herein are systems and methods for delivering medication, such as insulin, that are user-friendly, environmentally-friendly, lower cost, discreet, less prone to errors, and/or that deliver precise, repeatable doses of medication, as well as accessories for applying and managing the same. In embodiments, the system includes a wearable insulin pump having a patch-style form factor for adhesion to a user's body surface.
Absstract of: WO2026110048A1
The present invention provides an automated portable wireless diabetic foot risk profiler system. The system comprises portable devices include a first portable device (103) configured to perform neuropathy assessment by producing a vibration and tactile sensation and detecting the response of a patient, and a second portable device (104) configured to perform vascular assessment by measuring blood pressure and detecting pulse wave pattern of the patient. The central control panel (102) perform real-time data acquisition and processing of a data including response of a patient to said vibration and tactile sensation along with the blood pressure measurement and pulse wave patterns. The remote response button unit (105) is for getting response directly from the patient to capture the value of tactile and vibration sensation in real time. The remote server (101) is for remote synchronization of data and remote data management.
Absstract of: WO2026112485A1
The present disclosure is directed to a bio-feedback sensor in combination with AI and ML that can be implemented to optimize neuromodulation parameters for the management of a medical condition such a type II diabetes. The bio-feedback obtained by the sensors is optimized by the ML tools to predict and recommend the upregulation or downregulating the neuroregulators to modulate treatment. The algorithms could also learn to sense a life-threating pathological state, or bio-chemical imbalance, and in the case of diabetes a life-threating low blood sugar level the system overrides to stimulate the target fibers that control organs to regulate blood glucose levels.
Absstract of: WO2026112174A1
Methods are provided for generating pancreatic endocrine cells from pluripotent stem cells (PSCs) using epigenetic modifiers. A fusion protein comprising catalytically inactivated Cas9 (dCas9) and an embryonic ectoderm development (EED)-binding domain (EBdCas9) is used with guide RNAs (gRNAs) to target regulatory regions of transcriptional regulators including EOMES, PDX1, and NGN3. Sequential targeting of PDX1 and NGN3 promoters with EBdCas9 removes repressive H3K27me3 marks, increases activating H3K27ac modifications, and accelerates differentiation into insulin-producing β-cells. The methods significantly increase β-cell yields (~4-6 fold), reduce non-pancreatic lineage contaminants (CDX2+, SOX2+, enteroendocrine cells), enhance mitochondrial function, and produce glucose-responsive cells with superior functional maturation in vivo. The epigenetic interventions enforce pancreatic developmental fates while activating NGN3-dependent transcriptional programs necessary for endocrine cell differentiation, insulin secretion, and metabolic maturation. Cells and compositions produced by these methods are also provided.
Absstract of: WO2026111961A1
Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.
Nº publicación: US20260144933A1 28/05/2026
Applicant:
INSULET CORP [US]
INSULET CORPORATION
Absstract of: US20260144933A1
The disclosed embodiments are directed to methods for dynamically adjusting the total daily insulin requirements of a user during pregnancy, based on the gestational week. An initial estimate of the adjusted total daily insulin requirement may be calculated as a multiple of the pre-pregnancy total daily insulin requirement, based on an average scale factor from a population of pregnant women suffering from Type I diabetes mellitus. An automatic drug delivery device may adjust the initial estimate of the total daily insulin requirement based on blood glucose level readings from a continuous glucose monitor during the course of the pregnancy.
BOPI
Electronic site
